Carisma Therapeutics Inc.

Carisma Announces Latest Data from Phase 1 Clinical Trial of CT-0508 at 8th Annual CAR-TCR Summit

by
Carisma Announces Latest Data from Phase 1 Clinical Trial of CT-0508 at 8th Annual CAR-TCR Summit

Group 2 data available to date support primary safety and feasibility endpoints of single-day bolus dosing of CT-0508   New translational analyses combining group 1 & group 2 continue to support CAR-M mechanism of action, demonstrating a correlation between biomarkers and best overall response PHILADELPHIA, Sept. 1, 2023 /PRNewswire/ — Carisma Therapeutics Inc. (Nasdaq: CARM) … Read more

Carisma Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

by
Carisma Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Dosed first patient in Phase 1 clinical trial of CT-0508 in combination with KEYTRUDA® (pembrolizumab) in patients with HER2-overexpressing solid tumors Nominated additional oncology target as part of the Company’s collaboration with Moderna to develop in-vivo targeted CAR-M therapies Cash, cash equivalents and marketable securities of $117.1 million expected to fund company through 2024 PHILADELPHIA, … Read more